Inventor

Wei Lu

Inventor

Newton, MA, US

Overview

2015–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 23 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds40%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%

A61KPreparations for medical, dental or toiletry purposes22%

PatentTitleYear

10,807,976Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors2020 10,800,750Compounds and compositions for inhibition of FASN2020 10,577,329Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2020 10,550,098Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2020 10,550,099Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors2020 10,472,342Compounds and compositions for inhibition of FASN2019 10,457,655Compounds and compositions for inhibition of FASN2019 10,450,286Compounds and compositions for inhibition of FASN2019 10,414,752Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2019 10,407,419Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors2019 10,399,951Compounds and compositions for inhibition of FASN2019 10,294,206Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2019 10,280,150Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors2019 10,266,495Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2019 10,253,015Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2019 10,005,734Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2018 9,834,539Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors2017 9,815,817'Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors'2017 9,771,349'Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors'2017 9,624,216'Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors'2017 9,624,175'Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors'2017 9,334,267'RAF inhibitor compounds'2016 9,187,474'Raf inhibitor compounds'2015

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2015–2016Patents assigned to DECIPHERA PHARMACEUTICALS LLC (2)· patent assignee history

2015–2016Patents assigned to LILLY CO ELI (2)· patent assignee history

2015–2016Based in Lawrence, KS, US· patent location history

2017–2020Patents assigned to FORMA THERAPEUTICS INC (17)· patent assignee history

2017–2020Based in Newton, MA, US· patent location history

2019Patents assigned to FORMA TM2 INC (4)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
FORMA THERAPEUTICS INC	17	2017–2020
FORMA TM2 INC	4	2019
DECIPHERA PHARMACEUTICALS LLC	2	2015–2016
LILLY CO ELI	2	2015–2016

Locations

Location	Patents	Span
Newton, Massachusetts, US	21	2017–2020
Lawrence, KS, US	2	2015–2016